‘Client Commitment’ Theme of Ipsos Health Team’s Recent Expansions
Ipsos Health Continues to Build Presence, Offer with a Slew of Recruits
Thursday, April 14, 2011
New York, NY – In support of sustained growth and its commitment to clients, Ipsos Health, one of the fastest growing pharmaceutical market research agencies in North America, has fortified its practice through a number of key hires. In total, nine researchers have recently joined the company.
“Over the past couple years, we’ve reshaped our service offer to bring greater value to our clients during this time of transformational change in the pharmaceutical industry. Their receptivity to our innovative new approaches has resulted in the need to further expand our team,” says Fred LaManna, Senior Vice President with Ipsos Health. “With these new members of our team on board, we’re continuing to build our relationships with clients by helping them optimize their businesses.”
The new team members have been hired to support both Ipsos Health in both the U.S. and Canada.
In the U.S. business, seven new researchers have joined the group. Pauline Minch joined as a Senior Research Manager. Prior to Ipsos, Pauline was a senior market research analyst at marketRx. Sandra Weber is also a Senior Research Manager and was previously a consulting analyst with IMS Health. Working remotely from Perry, OH, Amy Moses joined the Ipsos Health as a Senior Research Manager. Amy brings ten years of market research experience to the team.
In addition, Research Associates Elisabeth Higgins, Jessica Stuart, Pooja Dagli and Ravi Makhiha have all joined Ipsos Health in the past two months.
In Toronto, two new Research Associates, Qasim Jawaid and Asfia Azam, have joined the Ipsos Health Canadian team.
“The addition of these researchers to the Ipsos Health team is a testament to our commitment to continuing to further strengthen our partnerships with our clients and to deliver commercially-meaningful insights,” says Elys Roberts, President of Ipsos Health. “Our newest members join the rest of the team with these objectives and excellence in research as their focus.”
For more information on this news release, please contact:
Senior Vice President
About Ipsos Health
Ipsos Health is a full-service, specialized custom research agency dedicated to delivering the commercially-meaningful market research that positively impacts brand performance for clients in the pharmaceutical, biotech, and medical device industries. With offices in 25 countries, our team is a blend of pharma market research experts, marketers and client-side brand-builders and market researchers. Drawing from a broad range of qualitative and quantitative techniques, we specialize in researching the motivations, experiences and influence of customers forming today’s multi-stakeholder healthcare markets.
Ipsos is a leading global survey-based market research company, owned and managed by research professionals. Ipsos helps interpret, simulate, and anticipate the needs and responses of consumers, customers, and citizens around the world.
Member companies assess market potential and interpret market trends. They develop and build brands. They help clients build long-term relationships with their customers. They test advertising and study audience
responses to various media. They measure public opinion around the globe.
Ipsos member companies offer expertise in advertising, customer loyalty, marketing, media, and public affairs research, as well as forecasting, modeling, and consulting. Ipsos has a full line of custom, syndicated,
omnibus, panel, and online research products and services, guided by industry experts and bolstered by advanced analytics and methodologies. The company was founded in 1975 and has been publicly traded
since 1999. In 2010, Ipsos generated global revenues of €1.140 billion ($1.6 billion U.S.).
Visit www.ipsos-na.com to learn more about Ipsos
offerings and capabilities.
Ipsos, listed on the Eurolist of Euronext – Comp B, is part of SBF 120 and the Mid-100 Index, adheres to the Next Prime segment and is eligible to the Deferred Settlement System. Isin FR0000073298, Reuters ISOS.PA, Bloomberg IPS:FP